中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

All Patients Enrolled in Phase III Clinical Study of Deunoxavir Marboxil for Pediatric Indication

Recently, the Phase III clinical study for pediatric indication of Deunoxavir Marboxil granules, an innovative anti-influenza drug jointly developed b...

2025-02-19
Simcere Pharmaceutical and Fermion Technology Collaborate to Develop China's First SSTR4-Targeting Analgesic

Jan. 17, 2025 – Simcere Pharmaceutical Group Co., Ltd. (2096.HK, "Simcere") and Guangzhou Fermion Technology Co., Ltd. ("Fermion")...

2025-02-12
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

Shanghai China, and NORTH CHICAGO, Ill USA., Jan 13 2025-- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie I...

2025-01-13
SIM0505, an ADC candidates Simcere Zaiming developed using proprietary technology platform, is entering trials both in China and the USA

Jan 3, 2025, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK) announce that SIM0505, a CDH6 ...

2025-01-06
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.